Oncology

The Use of Dietary Supplements in Oncology
The use of dietary supplements among patients affected by cancer is extensive, with an estimated 20-90 % of patients using these products. Their use of these products is often not shared with the treating physician. This is because patients perceive or believe that their physicians are indifferent or negative toward the use of dietary supplements. As a result, patients may obtain information a...


Diabetes mellitus and ovarian cancer: More complex than just increasing risk
Diabetes mellitus (DM) is a risk factor for endometrial cancer and is associated with poorer outcomes in breast and colon cancers. This association is less clear in epithelial ovarian cancer (EOC). We sought to examine the effect of DM on progression-free (PFS) and overall survival (OS) in women with EOC. A retrospective cohort study of EOC patients diagnosed between 2004 and 2009 at a single i...
A qualitative study of ovarian cancer survivors’ perceptions of endpoints and goals of care
A survey of the Ovarian Cancer National alliance revealed a communication gap between physicians and survivors. This qualitative study explored the space between perceptions in hopes of better defining treatment endpoints meaningful to treating physicians and their patients. a focus group of ovarian cancer survivors (n=22) was assembled via the survivor support network SHARE. a physician-guided...


Dysregulated MicroRNA Expression in Adenocarcinoma of the Uterine Cervix: Clinical Impact of miR-363-3p
Adenocarcinoma (ACA) of the uterine cervix is increasing in incidence and currently accounts for approximately 20% of all cervical malignancies. MicroRNAs (miRNAs) have been investigated as potential biomarkers of cervical cancer; however, their role in ACA remains unknown. Here, we characterized miRNA expression profiles and investigated miRNAs as diagnostic and prognostic factors in ACA. Eval...
Targeting HER2 in ovarian and uterine cancers: Challenges and future directions
Targeting the human epidermal growth factor receptor 2 (HER2) has yielded major advances in breast cancer treatment. Accordingly, it has generated interest in targeting HER2 to treat gynecologic malignancies. Multiple studies have evaluated the rates of HER2 overexpression and/or amplification in ovarian and uterine cancers. HER2 has also been studied as a prognostic factor but resulting data h...


CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy
To evaluate the different kinetic parameters of serum CA125 during neoadjuvant chemotherapy (NAC) to predict optimal interval debulking surgery (IDS). The present retrospective multicenter study included patients with advanced ovarian cancer treated with neoadjuvant platinum-based chemotherapy followed by IDS between 2002 and 2009. Demographic data, CA125 levels, radiographic data, chemotherapy...
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer
Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval debulking surgery (IDS) is the main objective of surgery in advanced epithelial ovarian cancer (EOC). The aim of this work was to evaluate the impact on survival of the number of neoadjuvant chemotherapy (NAC) cycles before IDS in EOC patients. Data from EOC patients (stages IIIC–IV), operated on between 1...

Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li–Fraumeni syndrome
Li–Fraumeni syndrome (LFS) is a rare genetic disease with a highly significant predisposition to multiple early-onset neoplasms. These neoplasms include adrenocortical carcinoma, sarcoma, leukemia and CNS tumors in children and sarcoma, breast cancer and lung cancer in adults. LFS is inherited in an autosomal dominant manner. In most patients germline mutations in the tumor suppressor gene TP...
A review of the evidence for occupational exposure risks to novel anticancer agents - A focus on monoclonal antibodies
IntroductionEvidence of occupational exposure risks to novel anticancer agents is limited and yet to be formally evaluated from the Australian healthcare perspective.MethodsFrom March to September 2013 medical databases, organizational policies, drug monographs, and the World Wide Web were searched for evidence relating to occupational exposure to monoclonal antibodies, fusion proteins, gene th...

Environmental contamination by cyclophosphamide preparation: Comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo
ObjectivesThe aim of this study was to compare environmental contamination of cyclophosphamide (CP) during 1 week of drug compounding by conventional manual procedure in a biological safety cabinet (BSC) with laminar airflow and a new robotic drug preparation system (APOTECAchemo).MethodsDuring four consecutive days, similar numbers of infusion bags with cyclophosphamide were prepared with both...
Bilateral synchronous adrenal metastasis of invasive ductal carcinoma treated with multimodality therapy including adrenalectomy and oophorectomy
A 38-year-old woman presented with a mass in the left breast. Biopsy of the lesion revealed invasive ductal carcinoma. Bilateral adrenal metastasis was detected in whole body positron emission tomography scanning. Needle biopsy of the left adrenal lesion proved infiltration of malignant cells from breast carcinoma. After eight cycles of neoadjuvant (preoperative) chemotherapy, mastectomy, bilat...

Use of naloxone for reversal of life-threatening opioid toxicity in cancer-related pain
ObjectiveTo review the emergency-based approach to opioid toxicity reversal in cancer-related pain patients.Data sourceA MEDLINE and PubMed search was conducted (1966 to May 2014) using the terms opioids, cancer, naloxone, respiratory depression, morphine, morphine derivatives, emergency, and anaphylaxis.Methods of study selectionEnglish articles in human subjects identified from the MEDLINE an...
Arrêt de la commercialisation des fils d’iridium 192 en France : proposition du groupe de curiethérapie de la Société française de radiothérapie oncologique
L’arrêt de la commercialisation des fils d’iridium 192 est intervenu au début de l’année 2014 en France. Cela a obligé les services de curiethérapie à reporter toutes leurs indications en utilisant des techniques avec projecteurs de source de débit pulsé ou de haut débit de dose. La plupart avaient déjà effectué cette migration pour une partie de leurs indications, selon les h...
Indications non oncologiques de la radiothérapie : quelles indications en 2014 ?
Cette revue actualise les indications non oncologiques de la radiothérapie, à l’exclusion des maladies traitées par radiochirurgie. Par rapport à la revue de 2005, les indications n’ont guère connu de grands changements : celles reconnues et validées restent la prévention des calfications osseuses hétéotopiques et des cheloïdes. En revanche, la prévention des resténoses coronar...
Guide des procédures de radiothérapie externe et de curiethérapie : présentation de la 2e édition
La première édition du guide des procédures de radiothérapie externe, parue en 2007, avait comme objectifs de produire des recommandations visant à optimiser, harmoniser et homogénéiser les pratiques. Cette seconde édition, incluant la curiethérapie, garde les mêmes objectifs en tenant compte des développements technologiques actuels (radiothérapie conformationnelle avec modulation ...